This innovative technology, developed by Canadian biotechnology company Innodal, uses antimicrobial peptides to eliminate the harmful pathogen. With its entry into the U.S. market, Innodal is set to launch industrial-scale projects with U.S. processing companies.
Listeria monocytogenes is feared by public health because it potentially has a high mortality rate. In a 2008 Canadian outbreak, that rate approached 40 percent.
INNEO is Innodal’s flagship product. It has been successfully commercialized in Canada for four years and will now be available in the U.S. market. Designed to target Listeria monocytogenes — a severe foodborne pathogen responsible for listeriosis — INNEO has proven significantly more effective than traditional chemical treatments in industry trials, particularly against strains that have led to major recalls in North America.
FoodWorld 